Adjunctive Intravitreal Anti-vascular Endothelial Growth Factor and Moxifloxacin Therapy in Management of Intraocular Tubercular Granulomas

References

• Gupta A, Gupta V. Tubercular posterior uveitis. Int Ophthalmol Clin. 2005;45(2):71–88. doi:10.1097/01.iio.0000155934.52589.e3.
   PubMedGoogle Scholar
• Thayil SM, Albini TA, Nazari H, et al. Local Ischemia and increased expression of vascular endothelial growth factor following ocular dissemination of mycobacterium tuberculosis. PLoS ONE. 2011;6(12):e28383. doi:10.1371/journal.pone.0028383.
   PubMed Web of Science ®Google Scholar
• Sharma K, Gautam N, Sharma M, et al. Ocular mycobacteriosis-dual infection of M. tuberculosis complex with M. fortuitum and M. bovis. J Ophthalmic Inflamm Infect. Dec 2017;7(1):2. doi:10.1186/s12348-016-0121-0.
   PubMedGoogle Scholar
• Oehlers S, Cronan M, Scott N, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature. 2015;517(7536):612–615. doi:10.1038/nature13967.
   PubMed Web of Science ®Google Scholar
• Gupta V, Gupta A, Rao NA. Intraocular tuberculosis—an update. Surv Ophthalmol. 2007;52:561–587.
   PubMed Web of Science ®Google Scholar
• Gupta V, Gupta A, Sachdeva N, et al. Successful management of tubercular subretinal granulomas. Ocul Immunol Inflamm. 2006;14(1):3–40. doi:10.1080/09273940500269939.
   Web of Science ®Google Scholar
• Agarwal M, Gupta C, Mohan KV, et al. Correlation of vascular endothelial growth factor with the clinical regression of tubercular granuloma. Indian J Ophthalmol. Sep 2020;68(9):2037–2040. doi:10.4103/ijo.IJO_1261_20.
   PubMed Web of Science ®Google Scholar
• Jain S, Agarwal A, Gupta V. Resolution of Large Choroidal Tuberculoma following Monotherapy with Intravitreal Ranibizumab. Ocul Immunol Inflamm. 2020;28(3):49–497. doi:10.1080/09273948.2019.1582786.
   PubMed Web of Science ®Google Scholar
• Jain S, Bajgai P, Tigari B, et al. Bevacizumab for paradoxical worsening treatment adjunct in HIV patient with choroidal tuberculoma. J Ophthalmic Inflamm Infect. 2016;6:42. doi:10.1186/s12348-016-0112-1.
   PubMed Web of Science ®Google Scholar
• Invernizzi A, Franzetti F, Viola F, et al. Optic nerve head tubercular granuloma successfully treated with anti-VEGF intravitreal injections in addition to systemic therapy. Eur J Ophthalmol. 2015;25:27–272.
   PubMed Web of Science ®Google Scholar
• Bansal R, Beke N, Sharma A, et al. Intravitreal bevacizumab as an adjunct in the management of a vascular choroidal granuloma. BMJ Case Rep. 2013;6:201.
   Google Scholar
• Babu K, Murthy P, Murthy K. Intravitreal bevacizumab as an adjunct in a patient with presumed vascularised choroidal tubercular granuloma. Eye. 2010;24:397–399. doi:10.1038/eye.2009.83.
   PubMed Web of Science ®Google Scholar
• Gupta A, Sharma A, Bansal R, et al. Classification of intraocular tuberculosis. Ocul Immunol Inflamm. 2015;23(1):7–13. doi:10.3109/09273948.2014.967358.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. Sep 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Cornel S, Adriana ID, Mihaela TC, et al. Anti-vascular endothelial growth factor indications in ocular disease. Rom J Ophthalmol. 2015;59(4):235–242.
   PubMedGoogle Scholar
• Matsuyama W, Hashiguchi T, Matsumuro K, et al. Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1120–1122. doi:10.1164/ajrccm.162.3.9911010.
   PubMed Web of Science ®Google Scholar
• Kumar NP, Banurekha VV, Nair D, et al. Circulating angiogenic factors as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis. PLoS One. 2016;11:e0146318. doi:10.1371/journal.pone.0146318.
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Abraham S, Sudharshan S. Paradoxical reactions in ocular tuberculosis. J Ophthalmic Inflamm Infect. 2019;9(1):19. doi:10.1186/s12348-019-0183-x.
   PubMed Web of Science ®Google Scholar
• Datta M, Via LE, Kamoun WS, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A. 2015;112:1827–1832. doi:10.1073/pnas.1424563112.
   PubMed Web of Science ®Google Scholar
• Sharma K, Gupta A, Sharma M, et al. The emerging challenge of diagnosing drug-resistant tubercular uveitis: experience of 110 eyes from North India. Ocul Immunol Inflamm. Jan 2, 2021;29(1):107–114. doi:10.1080/09273948.2019.1655581.
   PubMed Web of Science ®Google Scholar
• Bansal R, Sharma K, Gupta A, et al. Detection of Mycobacterium tuberculosis genome in vitreous fluid of eyes with multifocal serpiginoid choroiditis. Ophthalmology. Apr 2015;122(4):840–850. doi:10.1016/j.ophtha.2014.11.021.
   PubMed Web of Science ®Google Scholar
• Sharma K, Bansal R, Sharma A, et al. Successful treatment of rifampicin-resistant intraocular tuberculosis. Ocul Immunol Inflamm. Feb 2015;23(1):93–96. doi:10.3109/09273948.2014.888084.
   PubMed Web of Science ®Google Scholar
• Agarwal M, Patnaik G, and Agarwal S, et al. Tuberculous scleritis and multidrug resistance. Ocul Immunol Inflamm 8 . Jan 8, 2021. 1–10 doi:10.1080/09273948.2020.1853176.
   Google Scholar
• Sharma K, Sharma A, Bansal R, et al. Drug-resistant tubercular uveitis. J Clin Microbiol. Nov 2014;52(11):4113–4114. doi:10.1128/JCM.01918-14.
   PubMed Web of Science ®Google Scholar
• Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol. 2014;12(3):159–167. doi:10.1038/nrmicro3200.
   PubMed Web of Science ®Google Scholar
• Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. Jun 1996;64(6):2062–2069. doi:10.1128/iai.64.6.2062-2069.1996.
   PubMed Web of Science ®Google Scholar
• Kee AR, Gonzalez-Lopez JJ, Al-Hity A, et al. Anti-tubercular therapy for intraocular tuberculosis: a systematic review and meta-analysis. Surv Ophthalmol. 2016;61(5):628–653. doi:10.1016/j.survophthal.2016.03.001.
   PubMed Web of Science ®Google Scholar
• Saatci AO, Selver OB, and Yaman A, et al. Photodynamic therapy as an adjunct to systemic treatment in a case with unilateral presumed vascularized choroidal tuberculous granuloma. Int Ophthalmol 29 (4) . 2008;293–296 1-4 August 2009.
   PubMedGoogle Scholar
• Rodrigues LD, Serracarbassa LL, Rosa H, et al. Vasoproliferative tumor associated with presumed ocular tuberculosis: case report. Arq Bras Oftalmol. 2007;70(3):527–531. doi:10.1590/S0004-27492007000300025.
   PubMedGoogle Scholar
• Agarwal M, Paul L, Gupta C, et al. The blinding bug found in the eye. BMJ Case Reports CP. 2019;12:bcr-2018-227194.
   Google Scholar
• Cabral T, Lima LH, Polido J, et al. Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration. Int J Retina Vitreous. May 1, 2017;3:6. doi:10.1186/s40942-017-0066-y.
   PubMedGoogle Scholar
• Moisseiev E, Waisbourd M, Ben-Artsi E, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol. 2014;252:331–337. doi:10.1007/s00417-013-2495-0.
   PubMed Web of Science ®Google Scholar
• Kim M, Kim ES, Seo KH, et al. Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration. Indian J Ophthalmol. Jun 2016;64(6):427–433. doi:10.4103/0301-4738.187659.
   PubMed Web of Science ®Google Scholar
• Eng VA, Rayess N, Nguyen HV, et al. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration. PLoS One. May 5, 2020;15(5):e0232353. doi:10.1371/journal.pone.0232353.
   PubMed Web of Science ®Google Scholar
• Lau PE, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. Jul 24, 2018;2018:8567912. doi:10.1155/2018/8567912.
   PubMed Web of Science ®Google Scholar
• Grzybowski A, Told R, Sacu S, et al. Update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 2018;239:181–193. doi:10.1159/000486145.
   PubMed Web of Science ®Google Scholar